US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Articles published by Humanetics Corporation

News headline image
Humanetics Corporation to Present at Radiation Research Society 72nd Annual International Meeting
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Selected for Oral Presentation at 2026 Military Health System Research Symposium
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation to Present at Upcoming Investor Conference
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Announces Investigator-Initiated Phase 2 Trial in Patients with Non-Small Cell Lung Cancer and Underlying Interstitial Lung Disease
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation to Present at Upcoming Investor Conference
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Appoints Timothy E. Morris as Chief Operating Officer
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation to Host a Virtual Panel Focused on Unmet Needs in Radiation Oncology and Pulmonology
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation to Present at Radiation Research Society 71st Annual International Meeting
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation to Present at Upcoming Military Medical and Defense Conferences
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation to Participate in Benchmark Healthcare Investor Conference This Week
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Chief Medical Officer Is Featured Guest at U.S. Industry, National Security, and Healthcare Forum
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Secures Additional Funding to Advance Development of Its Drug to Prevent Radiation Injury
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Advances Development of Novel Radiation Protection Drug With New Study Results
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Presents at the 2024 Department of Defense Scientific Meeting
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics to Participate in the Bio Investor Forum in San Francisco
From Humanetics Corporation
Via Business Wire
News headline image
Uniformed Services University Awards Grant to Support Continued Collaboration with Humanetics to Develop Radiation Countermeasure
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation to Present at the BIO International Convention in San Diego
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation to Present at Investor and Partnering Conferences
From Humanetics Corporation
Via Business Wire
News headline image
Major General (Ret.) Barbara R. Holcomb Joins Board at Humanetics
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Publishes Positive Clinical Trial Results of BIO 300 in Patients with Non-Small Cell Lung Cancer
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Awarded Contract From Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury
From Humanetics Corporation
Via Business Wire
News headline image
BIO 300 Featured at the 2023 Military Health System Research Symposium
From Humanetics Corporation
Via Business Wire
News headline image
BIO 300 Enhances Radiotherapy Efficacy Against Lung Tumors in a Nonclinical Model
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Clinical Trial
From Humanetics Corporation
Via Business Wire
News headline image
BIO 300 Demonstrates Protection Against Radiation-Induced Lung Injury
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Presents at the MedInvest Oncology Investor Conference
From Humanetics Corporation
Via Business Wire
News headline image
Humanetics Corporation Publishes Phase 1 Trial Results for BIO 300 Oral Powder
From Humanetics Corporation
Via Business Wire